CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Total revenues	$ 2,357	$ 4,651	$ 7,418
Operating expenses:
Research and development	82,258	53,311	42,534
General and administrative	27,195	20,488	14,456
Intangible asset impairment		3,500	18,000
Gain on fair value remeasurement of contingent consideration	(6,862)	(1,405)	(4,218)
Litigation settlement related loss	15,000
Total operating expenses	117,591	75,894	70,772
Operating loss	(115,234)	(71,243)	(63,354)
Investment and other income, net	2,909	505	2,407
Net loss before income tax benefit	(112,325)	(70,738)	(60,947)
Income tax benefit		227	1,167
Net loss	$ (112,325)	$ (70,511)	$ (59,780)
Basic and diluted net loss per common share	$ (2.40)	$ (1.64)	$ (2.02)
Basic and diluted net loss per common share	$ (2.40)	$ (1.64)	$ (2.02)
Shares used in calculating basic and diluted net loss per share	46,888	42,870	29,640
Shares used in calculating basic and diluted net loss per share	46,888	42,870	29,640
Comprehensive loss:
Net loss	$ (112,325)	$ (70,511)	$ (59,780)
Other comprehensive income (loss):
Unrealized loss on marketable securities	(634)	(695)	(30)
Comprehensive loss	(112,959)	(71,206)	(59,810)
Product development and licensing agreements
Revenues:
Total revenues	56	31	2,301
Contracts and grants
Revenues:
Total revenues	$ 2,301	$ 4,620	$ 5,117